Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
AV fistula and graft creation, access circuit angioplasty and stenting. Main billing specialties: vascular surgery, interventional radiology and nephrology.
Medicare fee-for-service dialysis access cases in the 50 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 204 | 20,282−7.2%/yr | −7.2%/yr | 6.31.2× | 68% | 20,800 in 2030+0.5%/yr |
| Texas | 153 | 14,652−16%/yr | −16%/yr | 7.11.4× | 71% | 14,800 in 2030+0.2%/yr |
| New York | 109 | 13,452−13%/yr | −13%/yr | 7.71.5× | 80% | 12,500 in 2030−1.2%/yr |
| Florida | 93 | 10,783−15%/yr | −15%/yr | 5.01.0× | 68% | 10,100 in 2030−1%/yr |
| Illinois | 87 | 7,931−11%/yr | −11%/yr | 5.91.1× | 73% | 7,380 in 2030−1.2%/yr |
| New Jersey | 58 | 7,071−13%/yr | −13%/yr | 7.01.3× | 70% | 7,590 in 2030+1.2%/yr |
| Georgia | 74 | 6,490−18%/yr | −18%/yr | 7.81.5× | 72% | 6,500 in 20300%/yr |
| Michigan | 59 | 5,586−14%/yr | −14%/yr | 6.91.3× | 71% | 4,770 in 2030−2.6%/yr |
| Virginia | 50 | 5,185−16%/yr | −16%/yr | 5.11.0× | 61% | 5,340 in 2030+0.5%/yr |
| North Carolina | 55 | 5,158−18%/yr | −18%/yr | 5.41.0× | 66% | 4,610 in 2030−1.9%/yr |
| Pennsylvania | 59 | 4,916−14%/yr | −14%/yr | 3.80.7× | 50% | 4,300 in 2030−2.2%/yr |
| Maryland | 40 | 4,421−11%/yr | −11%/yr | 5.11.0× | 64% | 4,640 in 2030+0.8%/yr |
| Ohio | 46 | 4,014−15%/yr | −15%/yr | 3.80.7× | 68% | 3,930 in 2030−0.4%/yr |
| Arizona | 33 | 3,680−7.6%/yr | −7.6%/yr | 5.21.0× | 88% | 4,140 in 2030+2%/yr |
| Indiana | 35 | 3,475−14%/yr | −14%/yr | 5.11.0× | 60% | 2,970 in 2030−2.6%/yr |
| South Carolina | 30 | 3,370−11%/yr | −11%/yr | 5.11.0× | 29% | 3,610 in 2030+1.2%/yr |
| Tennessee | 37 | 2,923−15%/yr | −15%/yr | 4.30.8× | 53% | 3,040 in 2030+0.7%/yr |
| Massachusetts | 31 | 2,905−7.2%/yr | −7.2%/yr | 3.20.6× | 22% | 3,070 in 2030+0.9%/yr |
| Missouri | 31 | 2,606−17%/yr | −17%/yr | 4.40.8× | 32% | 2,570 in 2030−0.2%/yr |
| Alabama | 35 | 2,267−19%/yr | −19%/yr | 5.41.0× | 57% | 2,000 in 2030−2.1%/yr |
| Louisiana | 35 | 2,265−18%/yr | −18%/yr | 5.81.1× | 26% | 2,030 in 2030−1.8%/yr |
| Nevada | 20 | 2,124−8.8%/yr | −8.8%/yr | 7.71.5× | 96% | 2,190 in 2030+0.5%/yr |
| Washington | 30 | 2,051−12%/yr | −12%/yr | 2.80.5× | 19% | 1,780 in 2030−2.4%/yr |
| Wisconsin | 23 | 2,016−15%/yr | −15%/yr | 3.70.7× | 42% | 1,940 in 2030−0.6%/yr |
| Connecticut | 14 | 1,941−9.9%/yr | −9.9%/yr | 6.11.2× | 87% | 1,830 in 2030−1%/yr |
| Mississippi | 17 | 1,861−18%/yr | −18%/yr | 5.11.0× | 36% | 1,780 in 2030−0.7%/yr |
| Kentucky | 25 | 1,806−14%/yr | −14%/yr | 4.10.8× | 13% | 1,510 in 2030−3%/yr |
| Oklahoma | 31 | 1,548−12%/yr | −12%/yr | 3.30.6× | 12% | 1,570 in 2030+0.3%/yr |
| Kansas | 17 | 1,438−10%/yr | −10%/yr | 3.60.7× | 63% | 1,570 in 2030+1.4%/yr |
| Colorado | 23 | 1,386−15%/yr | −15%/yr | 3.00.6× | 39% | 1,300 in 2030−1.1%/yr |
| Minnesota | 31 | 1,328−18%/yr | −18%/yr | 3.10.6× | 42% | 1,660 in 2030+3.8%/yr |
| Arkansas | 13 | 1,246−12%/yr | −12%/yr | 3.40.7× | 62% | 1,150 in 2030−1.3%/yr |
| Oregon | 16 | 1,041−9.9%/yr | −9.9%/yr | 2.60.5× | 56% | 1,090 in 2030+0.7%/yr |
| Delaware | 7 | 781−12%/yr | −12%/yr | 4.70.9× | 89% | 780 in 20300%/yr |
| Iowa | 15 | 691−12%/yr | −12%/yr | 1.60.3× | 11% | 760 in 2030+1.5%/yr |
| New Mexico | 7 | 658−16%/yr | −16%/yr | 3.00.6× | 83% | 1,090 in 2030+8.7%/yr |
| Rhode Island | 3 | 655−9.9%/yr | −9.9%/yr | 7.51.5× | 100% | 610 in 2030−1.3%/yr |
| Utah | 9 | 647−6.1%/yr | −6.1%/yr | 3.10.6× | 40% | 580 in 2030−1.7%/yr |
| Hawaii | 8 | 567−14%/yr | −14%/yr | 4.60.9× | 62% | 560 in 2030−0.1%/yr |
| Nebraska | 7 | 526−11%/yr | −11%/yr | 2.10.4× | 3% | 610 in 2030+2.4%/yr |
| Idaho | 7 | 518−3.1%/yr | −3.1%/yr | 2.60.5× | 0% | 510 in 2030−0.2%/yr |
| Alaska | 8 | 491+1.8%/yr | +1.8%/yr | 4.10.8× | 49% | 400 in 2030−3.2%/yr |
| South Dakota | 11 | 440−12%/yr | −12%/yr | 3.50.7× | 10% | 460 in 2030+0.6%/yr |
| District of Columbia | 3 | 402−12%/yr | −12%/yr | 6.61.3× | 82% | 350 in 2030−2.1%/yr |
| North Dakota | 8 | 392−7.1%/yr | −7.1%/yr | 4.00.8× | 0% | 350 in 2030−1.8%/yr |
| New Hampshire | 6 | 354−13%/yr | −13%/yr | 1.60.3× | 0% | 380 in 2030+1.2%/yr |
| Maine | 4 | 340−15%/yr | −15%/yr | 2.20.4× | 5% | 390 in 2030+2.3%/yr |
| West Virginia | 2 | 305−22%/yr | −22%/yr | 1.50.3× | 0% | 350 in 2030+2.3%/yr |
| Montana | 1 | 182−11%/yr | −11%/yr | 1.00.2× | 0% | 260 in 2030+6.4%/yr |
| Wyoming | 1 | 101−4.5%/yr | −4.5%/yr | 0.90.2× | 0% | 100 in 2030+0.4%/yr |
Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 20 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 7 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Peca Labs | 5 |
| Vascutek | 5 |
| W L Gore & Associates | 4 |
| Merit Medical Systems | 3 |
| Atrium Medical | 1 |
| Maquet Cardiovascular | 1 |
| Vascular Flow Technologies | 1 |
Product codes: DSY (prosthesis, vascular graft, of 6mm and greater diameter), DYF (prosthesis, vascular graft, of less then 6mm diameter). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +5 pts since 2019, to 64%.
The 10 busiest do 34% of the cases CMS names in California; 76 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Peripheral arterial intervention | 1,321 | 182,726−5.9%/yr | −5.9%/yr | 215,300 in 2030+2.8%/yr |
| Superficial venous ablation | 1,980 | 166,794−4.1%/yr | −4.1%/yr | 191,600 in 2030+2.3%/yr |
| Thrombectomy, IVC filters & venous stents | 389 | 47,332+0.1%/yr | +0.1%/yr | 62,700 in 2030+4.8%/yr |
| Carotid revascularization | 741 | 36,694−5%/yr | −5%/yr | 40,000 in 2030+1.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 89 | 13,204−6.8%/yr | −6.8%/yr | 13,800 in 2030+0.7%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 12 companies reported engagement with surgeons in the covered states worth $256K in consulting, speaking, meals and travel tied to these products, about $149 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.